We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.82%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.17B
AUM Growth
+$18.3M
Cap. Flow
-$273M
Cap. Flow %
-4.42%
Top 10 Hldgs %
39.22%
Holding
178
New
12
Increased
57
Reduced
71
Closed
15

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$25.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
3
EXAS
Exact Sciences
EXAS
+$16.4M
4
ABT icon
Abbott
ABT
+$15.1M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$13M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$36.6M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$34.7M
3
CRL icon
Charles River Laboratories
CRL
+$33.2M
4
ARGX icon
argenx
ARGX
+$29.8M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.04%
3 Communication Services 0.02%
4 Technology 0.01%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
151
Rocket Pharmaceuticals
RCKT
$348M
$172K ﹤0.01%
9,300
-10,400
-53% -$213K
AUTL
152
Autolus Therapeutics
AUTL
$386M
$151K ﹤0.01%
41,500
+9,000
+28% +$35.9K
NAMS icon
153
NewAmsterdam Pharma
NAMS
$3.47B
$128K ﹤0.01%
+7,700
New +$133K
VCYT icon
154
Veracyte
VCYT
$4.52B
$123K ﹤0.01%
+3,600
New +$101K
A icon
155
Agilent Technologies
A
$39.1B
$114K ﹤0.01%
769
+65
+9% +$8.9K
ORCL icon
156
Oracle
ORCL
$331B
$106K ﹤0.01%
624
+53
+9% +$7.68K
NVDA icon
157
NVIDIA
NVDA
$5.01T
$87K ﹤0.01%
716
+61
+9% +$7.21K
MSFT icon
158
Microsoft
MSFT
$2.84T
$83.5K ﹤0.01%
194
+15
+8% +$6.41K
QCOM icon
159
Qualcomm
QCOM
$176B
$72.6K ﹤0.01%
427
+36
+9% +$6.36K
MTD icon
160
Mettler-Toledo International
MTD
$26.8B
$61.5K ﹤0.01%
41
+1
+3% +$1.4K
OABI icon
161
OmniAb
OABI
$294M
$48.5K ﹤0.01%
11,456
– –
LH icon
162
Labcorp
LH
$24.3B
$46K ﹤0.01%
206
+16
+8% +$3.52K
TEM
163
Tempus AI
TEM
$7.69B
$29.2K ﹤0.01%
516
-4,484
-90% -$210K
AAPL icon
164
Apple
AAPL
$4.89T
– –
-2,200
Closed -$463K
ALKS icon
165
Alkermes
ALKS
$8.82B
– –
-18,000
Closed -$434K
ATRC icon
166
AtriCure
ATRC
$1.77B
– –
-212,559
Closed -$4.84M
BCYC
167
Bicycle Therapeutics
BCYC
$270M
– –
-16,000
Closed -$324K
CCCC icon
168
C4 Therapeutics
CCCC
$376M
– –
-57,600
Closed -$266K
DVAX
169
DELISTED
Dynavax Technologies
DVAX
– –
-27,558
Closed -$309K
ETNB
170
DELISTED
89bio
ETNB
– –
-24,700
Closed -$198K
FDMT icon
171
4D Molecular Therapeutics
FDMT
$526M
– –
-15,700
Closed -$330K
OM icon
172
Outset Medical
OM
$74.9M
– –
-50,853
Closed -$2.94M
TDOC icon
173
Teladoc Health
TDOC
$1.58B
– –
-272,798
Closed -$2.67M
WST icon
174
West Pharmaceutical
WST
$23.1B
– –
-520
Closed -$171K
GRAL
175
GRAIL Inc
GRAL
$2.91B
– –
-7,266
Closed -$112K
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2024 Portfolio in Review

As of Q3 2024, Bellevue Group held 178 positions worth $6.17B, up 0.3% from $6.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group withdrew a net $273M in Q3 2024, closing 15 positions and reducing 71 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Terns Pharmaceuticals worth $8.69M.

  • Bellevue Group's largest Q3 2024 buy was Terns Pharmaceuticals: 1,042,135 shares worth $8.69M.
  • Bellevue Group added most to Evolent Health in Q3 2024, an estimated $25.8M increase.
  • Bellevue Group's biggest Q3 2024 reduction was Insmed, cutting an estimated $36.6M.
  • Bellevue Group fully exited Silk Road Medical, Inc. Common Stock in Q3 2024, selling an estimated $23.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $6.17B portfolio in Q3 2024.
  • Bellevue Group opened 12 new positions and closed 15 in Q3 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.17B.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.